The logo for the Food and Drug Administration is seen ahead of a news conference on removing synthetic dyes from America’s food supply, at the Health and Human Services Headquarters in Washington, DC on April 22, 2025.
Nathan Posner | Anadolu | Getty Images
Federal officials have approved another generic version of theĀ abortion pill mifepristone, a regulatory formality that quickly triggered pushback fromĀ anti-abortion groupsĀ and politicians aligned with the Trump administration.
Drugmaker Evita Solutions announced on its website that theĀ Food and Drug AdministrationĀ signed off on its low-cost form of theĀ pill, which is approved to end pregnancies through 10 weeks.
Students for Life Action, which opposes abortion, in a statement Thursday called the approval “a stain on the Trump presidency and another sign that the deep state at the FDA must go.”
Republican Sen. Josh Hawley of Missouri also criticized the move in a post on X, stating: “I have lost confidence in the leadership at FDA.”
The criticism comes as Republican President Donald Trump’s top health officials, including Health SecretaryĀ Robert F. Kennedy Jr., face growing pressure from abortion opponents to reevaluate mifepristone, which was approved 25 years ago and has repeatedly been deemed safe and effective by FDA scientists.
In a letter to Republican attorneys general last month, Kennedy and FDA Commissioner Dr. Marty Makary pledged to conduct a full review of the drug’s safety.
The FDA approved the original version of mifepristone in 2000 and gradually eased access over time. That included approving the first generic pill, from drugmaker GenBioPro, in 2019.
In 2021, the FDA under Democratic President Joe Biden permitted online prescribing and mail-order delivery of the drug, greatly expanding access. Abortion opponents have been fighting the change ever since.
Approval of generic drugs is typically a rote process at the FDA, with multiple copycat versions usually approved after the patent on the original drug expires. In most cases, generic drugmakers only need to show that their drug matches the ingredients and formula developed by the original drugmaker.
The FDA typically approves such applications within 10 months. But filing documents posted to the FDA’s website show that Evita Solutions filed its application to market mifepristone four years ago.
The company did not immediately respond to requests for comment.
On its website, Evita states that it “believes that all people should have access to safe, affordable, high-quality, effective, and compassionate abortion care.”
Approval of a second generic is unlikely to affectĀ access to the pill, which is typically taken with another drug, misoprostol. The combination accounts for roughly two-thirds of all U.S. abortions. Mifepristone dilates the cervix and blocks the hormone progesterone, while misoprostol causes the uterus to cramp and contract.
Access to mifepristone isĀ restrictedĀ across large sections of the country because of state laws that ban abortion ā including medication abortion ā or impose separate restrictions on the drug’s use. Those laws are subject to a number ofĀ ongoing lawsuitsĀ that are winding their way throughĀ the legal system.
Restrictions on the pill are not supported by most major medical societies, including the American Medical Association.
